A credible path to FY2026 profitability can reframe this as durable infrastructure for AI-accelerated biology rather than a cyclical research supplier. Upside depends on sequencing-workflow reacceleration and turning biosecurity/provenance into paid, sticky features.

As AI makes biological design cheap, the scarce bottleneck shifts to trusted, high-throughput DNA “writing” embedded in regulated workflows; if Twist sustains synthesis + sequencing-workflow growth and reaches FY2026 adjusted EBITDA breakeven, it can compound into a de-risked “DNA infrastructure” supplier by 2031.

AI accelerates experiment design (more demand for DNA/controls), while tightening biosecurity/provenance requirements reward trusted suppliers; less tied to the compute flywheel than model builders.

The non-linear upside is not “more gene orders,” it’s embedding into high-frequency workflows where reliability, compliance, and integration matter: (1) expand sequencing-workflow consumables as large-customer transitions normalize, (2) attach regulated controls/provenance features that enterprises pay for, and (3) reduce waste via manufacturing prediction and pricing discipline. If the FY2026 profitability milestone is hit, investor attention can shift from liquidity/dilution to durable operating leverage.

The growth setup is real, but the path is narrow: (1) the FY2026 adjusted EBITDA breakeven gate, (2) commoditization/price-down vs manufacturing learning-curve, (3) biosecurity/export-control compliance that may become a cost center, and (4) discontinuity risk from customer concentration and a critical single-source input.

$44.67